Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Other Non-Current Assets (2020 - 2022)

Quantum Biopharma's Other Non-Current Assets history spans 3 years, with the latest figure at $8.8 million for Q1 2022.

  • On a quarterly basis, Other Non-Current Assets rose 0.64% to $8.8 million in Q1 2022 year-over-year; TTM through Mar 2022 was $8.8 million, a 0.64% increase, with the full-year FY2021 number at $8.6 million, changed 0.43% from a year prior.
  • Other Non-Current Assets hit $8.8 million in Q1 2022 for Quantum Biopharma, up from $8.6 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for QNTM hit a ceiling of $9.2 million in Q1 2020 and a floor of $8.2 million in Q3 2020.
  • Historically, Other Non-Current Assets has averaged $8.7 million across 3 years, with a median of $8.6 million in 2021.
  • The widest YoY moves for Other Non-Current Assets: up 4.59% in 2021, down 5.09% in 2021.
  • Tracing QNTM's Other Non-Current Assets over 3 years: stood at $8.6 million in 2020, then increased by 0.43% to $8.6 million in 2021, then rose by 1.46% to $8.8 million in 2022.
  • Business Quant data shows Other Non-Current Assets for QNTM at $8.8 million in Q1 2022, $8.6 million in Q4 2021, and $8.6 million in Q3 2021.